CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are freque...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/13/12/418 |
| id |
doaj-ac55667eb7484dc7ac5a898b88795d82 |
|---|---|
| record_format |
Article |
| spelling |
doaj-ac55667eb7484dc7ac5a898b88795d822020-11-27T07:52:49ZengMDPI AGPharmaceuticals1424-82472020-11-011341841810.3390/ph13120418CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer TreatmentLisa Scheiblecker0Karoline Kollmann1Veronika Sexl2Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210 Vienna, AustriaInstitute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210 Vienna, AustriaInstitute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210 Vienna, AustriaDespite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are frequently deregulated in cancer and signify vulnerable nodes and potential therapeutic targets. We here focus on the cell cycle kinase CDK6 and on the MAPK pathway and on their interplay. We also provide an overview on clinical studies examining the effects of combinational treatments currently explored for several cancer types.https://www.mdpi.com/1424-8247/13/12/418CDK6MAPKp38combinationalpalbociclibinhibitors |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Lisa Scheiblecker Karoline Kollmann Veronika Sexl |
| spellingShingle |
Lisa Scheiblecker Karoline Kollmann Veronika Sexl CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment Pharmaceuticals CDK6 MAPK p38 combinational palbociclib inhibitors |
| author_facet |
Lisa Scheiblecker Karoline Kollmann Veronika Sexl |
| author_sort |
Lisa Scheiblecker |
| title |
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
| title_short |
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
| title_full |
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
| title_fullStr |
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
| title_full_unstemmed |
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
| title_sort |
cdk4/6 and mapk—crosstalk as opportunity for cancer treatment |
| publisher |
MDPI AG |
| series |
Pharmaceuticals |
| issn |
1424-8247 |
| publishDate |
2020-11-01 |
| description |
Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are frequently deregulated in cancer and signify vulnerable nodes and potential therapeutic targets. We here focus on the cell cycle kinase CDK6 and on the MAPK pathway and on their interplay. We also provide an overview on clinical studies examining the effects of combinational treatments currently explored for several cancer types. |
| topic |
CDK6 MAPK p38 combinational palbociclib inhibitors |
| url |
https://www.mdpi.com/1424-8247/13/12/418 |
| work_keys_str_mv |
AT lisascheiblecker cdk46andmapkcrosstalkasopportunityforcancertreatment AT karolinekollmann cdk46andmapkcrosstalkasopportunityforcancertreatment AT veronikasexl cdk46andmapkcrosstalkasopportunityforcancertreatment |
| _version_ |
1724414169209372672 |